NPTX2 and prostate carcinoma: To further confirm that the low expression of NPTX2 in prostate cancer is due to promoter methylation, we treated DU145, PC3 and C4-2 cell lines with the demethylating agent 5-aza-2′-deoxycytidine (5-AZA-dC).